These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19373083)

  • 21. Probucol does not inhibit myeloperoxidase-dependent low-density lipoprotein oxidation as a potent protective effect in atherosclerosis.
    Van Antwerpen P; Néve J; Moreau P; Boudjeltia KZ; Vanhaeverbeek M; Prévost M; Babar S; Legssyer I; Moguilevsky N; Ducobu J
    J Cardiovasc Pharmacol; 2007 Sep; 50(3):350-1. PubMed ID: 17878766
    [No Abstract]   [Full Text] [Related]  

  • 22. Thiazolidinediones: antidiabetic drugs with cardiovascular effects.
    Pastromas S; Koulouris S
    Hellenic J Cardiol; 2006; 47(6):352-60. PubMed ID: 17243507
    [No Abstract]   [Full Text] [Related]  

  • 23. Hyperelongated biglycan: the surreptitious initiator of atherosclerosis.
    Little PJ; Osman N; O'Brien KD
    Curr Opin Lipidol; 2008 Oct; 19(5):448-54. PubMed ID: 18769225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New therapeutic agents for diabetes mellitus: implications for anesthetic management.
    Chen D; Lee SL; Peterfreund RA
    Anesth Analg; 2009 Jun; 108(6):1803-10. PubMed ID: 19448205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunomodulation with DiNAC-- a new approach to the treatment of atherosclerosis?
    Doggrell SA
    Expert Opin Investig Drugs; 2002 May; 11(5):717-20. PubMed ID: 11996652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel nano-encapsulation of probucol in microgels: scanning electron micrograph characterizations, buoyancy profiling, and antioxidant assay analyses.
    Mooranian A; Zamani N; Mikov M; Goločorbin-Kon S; Stojanovic G; Arfuso F; Al-Salami H
    Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S741-S747. PubMed ID: 30260253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stability and biological testing of taurine-conjugated bile acid antioxidant microcapsules for diabetes treatment.
    Mooranian A; Zamani N; Mikov M; Goločorbin-Kon S; Stojanovic G; Arfuso F; Al-Salami H
    Ther Deliv; 2019 Feb; 10(2):99-106. PubMed ID: 30729887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors.
    Rizzo M; Rizvi AA; Spinas GA; Rini GB; Berneis K
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1495-503. PubMed ID: 19758106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Curcumin and the cellular stress response in free radical-related diseases.
    Calabrese V; Bates TE; Mancuso C; Cornelius C; Ventimiglia B; Cambria MT; Di Renzo L; De Lorenzo A; Dinkova-Kostova AT
    Mol Nutr Food Res; 2008 Sep; 52(9):1062-73. PubMed ID: 18792015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular docking of γ-sitosterol with some targets related to diabetes.
    Balamurugan R; Stalin A; Ignacimuthu S
    Eur J Med Chem; 2012 Jan; 47(1):38-43. PubMed ID: 22078765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
    Shinkai H
    Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apoprotein A-I mimetic peptides and their potential anti-atherogenic mechanisms of action.
    Getz GS; Wool GD; Reardon CA
    Curr Opin Lipidol; 2009 Jun; 20(3):171-5. PubMed ID: 19373084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?
    Giugliano D; Standl E; Vilsbøll T; Betteridge J; Bonadonna R; Campbell IW; Schernthaner GH; Staels B; Trichopoulou A; Farinaro E
    Acta Diabetol; 2009 Sep; 46(3):173-81. PubMed ID: 19543848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice.
    Anandharajan R; Sayyed SG; Doshi LS; Dixit P; Chandak PG; Dixit AV; Brahma MK; Deshmukh NJ; Gupte R; Damre A; Suthar J; Padigaru M; Sharma SD; Nemmani KV
    Metabolism; 2009 Oct; 58(10):1503-16. PubMed ID: 19608207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promising Potential of Dietary (Poly)Phenolic Compounds in the Prevention and Treatment of Diabetes Mellitus.
    Dias TR; Alves MG; Casal S; Oliveira PF; Silva BM
    Curr Med Chem; 2017; 24(4):334-354. PubMed ID: 27593957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ecdysterone and its activity on some degenerative diseases.
    Cahlíková L; Macáková K; Chlebek J; Host'álková A; Kulhánková A; Opletal L
    Nat Prod Commun; 2011 May; 6(5):707-18. PubMed ID: 21615037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antidiabetic agents].
    Oudart N
    Rev Infirm; 1999 May; (49):20-6. PubMed ID: 10652870
    [No Abstract]   [Full Text] [Related]  

  • 38. Metformin--the gold standard in type 2 diabetes: what does the evidence tell us?
    Bosi E
    Diabetes Obes Metab; 2009 May; 11 Suppl 2():3-8. PubMed ID: 19385978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study.
    Mooranian A; Raj Wagle S; Kovacevic B; Takechi R; Mamo J; Lam V; Watts GF; Mikov M; Golocorbin-Kon S; Stojanovic G; Al-Sallami H; Al-Salami H
    Sci Rep; 2020 Jan; 10(1):106. PubMed ID: 31919411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacotherapy of hyperglycemia.
    Kulasa KM; Henry RR
    Expert Opin Pharmacother; 2009 Oct; 10(15):2415-32. PubMed ID: 19743938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.